Drugs / LEAF-4L6715
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06640777 | Nov 2024 → Nov 2026 expected | acute respiratory distress syndrome | LEAF4Life, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEAF-4L6715 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06640777 ↗ |
| Route | Intravenous | “LEAF-4L6715 administered Intravenously 200 mg every 12h for 2 days” NCT06640777 ↗ |